OpenAI and SpaceX now command an estimated $18 billion in secondary-market activity across the past twelve months, according to aggregated broker desk flow and regulatory filings reviewed by allocators with direct exposure. The two companies represent roughly 43% of all venture secondary volume in that period, creating a liquidity choke point unseen since the 2021 SPAC wave concentrated risk into a handful of pre-IPO names. The buyer pools are small—fewer than 80 institutional accounts globally have the risk appetite and governance clearance to write eight-figure secondary checks into either company. The result is a market structure that resembles less a liquid secondary exchange and more a private club with rotating chairs.

The concentration accelerated in the first quarter of this year. OpenAI secondary transactions cleared at valuations between $340 and $380 per share, implying a company valuation near $150 billion, while SpaceX shares traded in a tight band around $135, valuing the company at roughly $250 billion. Those prices held even as public comparables in AI infrastructure and aerospace manufacturing sold off by 12% and 9% respectively. The divergence suggests secondary buyers are pricing in not current fundamentals but anticipated liquidity events—an OpenAI public offering in late 2026 or early 2027, and SpaceX's Starship commercialization milestones that could justify a $300 billion valuation by year-end. The problem is that both events remain speculative, and the buyer base is not diversifying. The same 30 to 40 family offices, sovereign wealth vehicles, and crossover funds appear as counterparties in nearly every secondary transaction above $5 million.

What makes this concentration dangerous is not the size of the positions but the illiquidity of the exit. OpenAI has conducted four tender offers in the past 18 months, but each was oversubscribed by a factor of 3-to-1, meaning sellers could only liquidate a fraction of their requested volume. SpaceX runs even tighter liquidity windows, with tender offers occurring roughly every six months and capped at $500 million to $750 million per round. If a family office or fund needs to exit a $20 million position quickly, there is no market. The secondary brokers who facilitate these trades report that bids dry up within 48 hours if a seller signals distress. The pricing power has shifted entirely to the companies, which control tender timing, volume, and participant lists. That means secondary holders are not truly liquid—they are guests in a queue, waiting for the next invitation.

The implications extend beyond the secondary market. Public venture funds with exposure to OpenAI or SpaceX are marking positions at or near the last tender price, but those marks assume liquidity that does not exist. If either company delays a public offering or its valuation resets downward due to revenue miss or regulatory friction, the mark-to-market losses will cascade through portfolios that have already committed dry powder to follow-on rounds. The leverage is hidden but real. Several crossover funds used lines of credit to participate in recent tenders, betting that liquidity would arrive within 12 to 18 months. If it does not, those funds face margin calls or forced asset sales into an already narrow market.

Operators and allocators should watch three triggers. First, the timing and structure of OpenAI's next tender offer, expected in late Q3 or early Q4 2026. If the company reduces the total volume or tightens eligibility, it will signal that internal liquidity is under strain. Second, SpaceX's Starship revenue contracts—if the company books fewer than $2 billion in firm commitments by year-end, the $300 billion valuation thesis breaks. Third, crossover fund redemption notices, which typically appear 90 days before quarter-end. If redemptions spike in Q3, funds with illiquid OpenAI or SpaceX stakes will be forced to liquidate more liquid positions first, amplifying volatility in public venture comparables.

The secondary market for these two names is not broadening. It is narrowing into a small group of buyers with overlapping risk profiles, pricing in liquidity that neither company has committed to provide. The shares trade, but the market does not.